The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Society of Cardiology Congress 2021 Industry Session Sponsored by Bayer August 27–30, 2021
Presentations of the Bayer Industry Symposium at the ESC Congress 2021
Thank you for your interest! See below to watch the session recording of the ESC symposium video.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Sunday 29 August, 2021 | 16:50 - 17:20 CEST | On Demand
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D
Stefan Anker, Michele Senni and Gerasimos Filippatos discuss how to improve cardiorenal outcomes in patients with CKD and T2D, suggesting finerenone (a novel, selective, nonsteroidal MRA) may be an effective treatment for kidney and CV protection in patients with CKD and T2D. Clinical data from the FIGARO-DKD and FIDELIO-DKD trials is presented, providing insights into the cardiovascular and kidney benefits of MR antagonism.
Session type: Satellite Symposium Faculty: Stefan Anker, Michele Senni, Gerasimos Filippatos
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
View Video
More Information
For more information regarding Finerenone visit us by clicking the link below
The compound presented is approved for use by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D) but is investigational or being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
Date accessed: 1 September, 2021
MA-M_FIN-ALL-0422-1